Scholar Rock Holding (Nasdaq:SRRK) - Stock Price, News & Analysis

SRRK Stock Overview

SRRK fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Cotiza un 80.4% por debajo de nuestra estimación de su valor razonable

Risk Analysis

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas se han diluido en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Venta significativa de accionistas con acceso a información confidencial en los últimos 3 meses

+ 1 more risk

Scholar Rock Holding Corporation Competitors

Viridian Therapeutics

NasdaqCM:VRDN

US$1.1b

Ambrx Biopharma

NasdaqGS:AMAM

US$1.8b

4D Molecular Therapeutics

NasdaqGS:FDMT

US$1.5b

Morphic Holding

NasdaqGM:MORF

US$1.6b

Price History & Performance

Summary of all time highs, changes and price drops for Scholar Rock Holding
Historical stock prices
Current Share Price	US$15.72
52 Week High	US$21.17
52 Week Low	US$5.56
Beta	0.89
1 Month Change	0.26%
3 Month Change	-5.53%
1 Year Change	94.55%
3 Year Change	-56.30%
5 Year Change	-7.26%
Change since IPO	1.42%

Recent updates

Scholar Rock: Solid Data And Good Prospects

Jan 12

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

Mar 01

Shareholder Returns

	SRRK	US Biotechs	US Market
7D	4.8%	-1.0%	-0.2%
1Y	94.6%	7.6%	25.7%

Rentabilidad frente al sector: SRRK superó al sector US Biotechs , que obtuvo un rendimiento del -4.2% el año pasado.

Rentabilidad vs. Mercado: SRRK superó al mercado US, que obtuvo un rendimiento del 14.9% el año pasado.

Price Volatility

Is SRRK's price volatile compared to industry and market?
SRRK volatility
SRRK Average Weekly Movement	11.0%
Biotechs Industry Average Movement	11.9%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de SRRK ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: SRRK(10%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2012	150	Jay Backstrom	https://scholarrock.com

Scholar Rock Holding Corporation, empresa biofarmacéutica, se centra en el descubrimiento, desarrollo y administración de medicamentos para el tratamiento de enfermedades graves en las que la señalización por factores de crecimiento proteicos desempeña un papel fundamental. La empresa desarrolla Apitegromab, un inhibidor de la activación de la miostatina que se encuentra en ensayo clínico de fase 3 para el tratamiento de la atrofia muscular espinal; y SRK-181, que ha completado ensayos clínicos de fase 1 para el tratamiento de cánceres resistentes a terapias con inhibidores de puntos de control, como las terapias con anticuerpos anti-PD-1 o anti-PD-L1. Está desarrollando una cartera de productos candidatos para administrar terapias novedosas para tratar una serie de enfermedades graves, como trastornos neuromusculares, trastornos cardiometabólicos, cáncer, fibrosis y anemia con restricción de hierro.

Scholar Rock Holding Corporation Fundamentals Summary

How do Scholar Rock Holding's earnings and revenue compare to its market cap?
SRRK fundamental statistics
Market cap	US$1.31b
Earnings (TTM)	-US$165.79m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-7.4x

P/E Ratio

Is SRRK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SRRK income statement (TTM)
Revenue	US$0
Cost of Revenue	US$121.90m
Gross Profit	-US$121.90m
Other Expenses	US$43.89m
Earnings	-US$165.79m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.13
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	22.2%

How did SRRK perform over the long term?

See historical performance and comparison

SRRK Stock Overview

Rewards

Risk Analysis

Scholar Rock Holding Corporation Competitors

NasdaqCM:VRDN

US$1.1b

NasdaqGS:AMAM

US$1.8b

NasdaqGS:FDMT

US$1.5b

NasdaqGM:MORF

US$1.6b

Price History & Performance

Recent News & Updates

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Recent updates

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates

Price target decreased to US$44.67

Price target decreased to US$46.17

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Price target decreased to US$55.80

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Board Member notifies of intention to sell stock

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress